Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics is attractive because the December 2024 Greenbrook TMS acquisition turned it into a vertically integrated interventional psychiatry platform with 93 centers, expanding its reach beyond a pure device model and creating operating leverage in a fragmented market. Q2 2026 showed the strategy working, with revenue of $41.6M, gross margin of 51.1%, and first-time positive adjusted EBITDA of $0.3M, while cash collections outpaced revenue and operating expenses were cut to $22.7M. Its three-path NeuroStar go-to-market reset, 50% clinic occupancy, and collaboration with Compass around potential 2027 psilocybin therapy all support a longer runway for growth, margin expansion, and category leadership.

Neuronetics is challenged by inconsistent commercial execution, slowing procedure volumes, and limited adoption of new products, which can restrain revenue growth despite its market-leading TMS franchise. The company also faces pricing pressure, competition, regulatory delays, and higher-than-expected operating expenses, all of which can compress margins and weaken the path to durable profitability. Although total cash reached $25.0M at Q2 and operating/investing cash use was -$1.4M, the need for ATM funding and the guided -$10.5M to -$14.5M full-year cash outflow underscore ongoing financing risk.